To evaluate quality of life (QoL) in patients with axial spondyloarthritis (axSpA) and its association with disease activity, functionality, structural damage, and spinal mobility, using patient-reported outcomes. This was an observational, cross-sectional, and single-center study in which 100 consecutive patients with axSpA were included. We obtained from all patients' sociodemographic data and values related to disease activity, functionality, structural damage, mobility, and quality of life. The Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) was considered as the primary outcome. Pearson r statistic, Student's T test, and univariate and multivariate linear regressions were performed to relate ASQoL with the studied covariates. Mean ASQoL score in all patients was 4.02 ± 2.81, with statistically significant differences between male and female (3.61 ± 2.80 vs. 4.83 ± 2.70). Patients with high disease activity (measured by the ASAS-endorsed Disease Activity Score, ASDAS > 2.1) showed higher mean score in ASQoL than those with low disease activity (ASDAS ≤ 2.1) (3.21 ± 0.74 vs. 1.43 ± 0.43, p < 0.001). ASQoL presented a significant linear correlation with BASDAI, BASFI, and ASDAS (r > 0.60). However, disease duration was not significantly correlated with ASQoL. Finally, the 68.9% of the ASQoL variability (R = 0.689) was determined by BASDAI, BASFI, and mSASSS, presenting mSASSS a negative regression coefficient (- 0.035). In our study, the impairment of QoL was mainly associated with disease activity (BASDAI) and worsening of functionality (BASFI). However, there is an inverse relationship between the worsening of QoL and structural damage. In addition, disease duration does not seem to influence the patient's welfare.

BackgroundAxial spondyloarthritis (AxSpA) is an inflammatory disease that mainly affects the spine. As the disease progresses, there is a reduction of quality of life (QOL) in patients due to loss of mobility and function, and also by episodes of inflammation and stiffness (disease activity).ObjectivesTo Analyze relationship between QOL of patients with AxSpA and other commonly used indicators in assessing these patients.Methods100 patients with AxSpA (67% male, age 48.38±11.05, disease duration 14.37±10.74, HLAB27 + 85%) were included. QOL of patients was assessed by the Ankylosing Spondylitis Quality of Life index (ASQoL). Mobility was evaluated by conventional metrology and by a new motion capture system (UCOTrack) and UCOASMI as its metrological index [1]. PRO questionnaries were completed to evaluate activity, function and overall status. Structural damage was scored by mSASSS index. To analyze relationship, Spearman tests, ANOVA and multiple linear regression were performed.ResultsASQoL showed statistically significant correlations with BASFI, BAS-G, ASDAS and UCOASMI. No significant correlations between QOL and structural damage, neither B27+, or having nr-AxSpA were found. Table shows results groupped by sex, B27, duration, nr-AxSpA (mSASSS <5 Duration>5 years) high activity level and poor mobility with statistical significance. Variables that were independently associated with ASQOL, in a multivariable linear regresion, were gender (p=0.027), BASDAI (p=0.008) and BASFI (p<0.001) R2 =0.676. Repeating this analysis, but including mobility measures obtained by motion capture, variables that were independently associated with ASQoL were BASDAI (p=0.000) lateral flexion defined by the position of shoulders and hips (p=0.004) and tilt of C7-L4 (p=0.023) R2 =0.609.Table 1TotalMale/FemaleB27+/B27−Duration >10/Duration <10AxSpA/nr-AxSpAASDAS >2.1/ASDAS <2.1UCOASMI >4/UCOASMI <4Patients (n)10067/3385/1560/4072/2866/3458/42ASQoL4.0 (2.8)3.6 (2.8)/4.8 (2.7)*3.8 (2.7)/4.8 (3.4)4.0 (2.65)/3.8 (3.12)4.0 (2.7)/3.9 (2.9)5.2 (2.6)/1.9 (1.9)**5.0 (2.6)/2.6 (2.3)**ASDAS2.6 (1.0)2.5 (1.0)/2.8 (1.1)2.5 (1.0)/2.9 (1.2)2.7 (1.01)/2.5 (1.20)2.6 (1.0)/2.4 (1.0)3.2 (0.7)/1.4 (0.4)**3.0 (1.0)/1.8 (0.7)**BASFI3.8 (2.8)3.7 (3.0)/4.0 (2.6)3.7 (2.8)/4.3 (3.3)4.0 (2.94)/3.3 (2.86)4.0 (2.8)/3.3 (2.9)5.2 (2.6)/1.6 (1.6)**5.3 (2.6)/1.8 (1.7)**BASG4.7 (2.6)4.3 (2.5)/5.3 (2.7)4.7 (2.6)/4.6 (2.5)4.6 (2.5)/4.6 (2.8)4.7 (2.6)/4.5 (2.5)6.1 (2.0)/1.9 (1.2)**5.5 (2.4)/3.6 (2.4)**UCOASMI4.7 (1.8)4.8 (2.0)/4.6 (1.4)4.7 (1.8)/4.5 (2.0)5.1 (1.9)/3.9 (1.4)**5.0 (1.9)/3.8 (1.3)**5.3 (1.6)/4.1 (1.9)*5.9 (1.5)/3.1 (0.6)**mSASSS14.4 (16.3)18.1 (18.7)/6.9 (3.9)**14.4 (16.6)/14.7 (15.9)17.3 (17.7)/8.3 (7.6)**18.7 (17.4)/3.3 (1.5)**16.2 (17.3)/16.7 (19.2)19.6 (19.5)/7.2 (5.1)*** p<0.05, ** p<0.001.ConclusionsQOL in AxSpA is influenced by the activity of the disease, and by decreased mobility. Women perceive a lower QOL. The best measure related to QOL is lateral bending. Improving patient mobility through exercise and finding appropriate treatment to decrease ...